UNSPSC 51172505: Chlorpheniramine/epinephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD900. This VA Drug Class (AD900) classifies this compound as belonging to the group ANTIDOTES/DETERRENTS, OTHER.

UNSPSC 51172505 Chlorpheniramine/epinephrine is a Commodity code covering pharmaceutical products and related supplies purchased by state and local health agencies, departments of administration, and cooperative purchasing organizations. State and local governments use this code for procurement of emergency pharmaceuticals, over-the-counter medications, and related health system supplies. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP administered by Minnesota Department of Administration). The code reflects a mix of direct pharmaceutical procurement for emergency response and community health initiatives alongside broader sourcing arrangements for generic and OTC product distribution through authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota through three representative opportunities. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, moving away from traditional pharmacy benefit manager intermediaries toward direct state-manufacturer relationships. Minnesota's MMCAP released RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded contracts effective July 1, 2026. Vendors must comply with cGMP, Drug Supply Chain Security Act requirements, and FDA regulations, with pricing weighted heavily (75 percent) in MMCAP's evaluation and administrative fees of 3 percent assessed on contract purchases.